Gurvinder Sodhi, MD
Psychiatry · Peoria, AZNPI 1477517076
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 99.9% of the total across 511 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. It is spread thinly across 27 manufacturers, the largest accounting for just 14.1% — the pattern of someone who eats at a lot of different presentations. Among psychiatry clinicians in AZ with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 511 payments — averaging $16.84 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AbbVie$1K
- ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.)$1K
- Teva Pharmaceuticals USA, Inc.$814
- Otsuka America Pharmaceutical, Inc.$809
- Lundbeck LLC$738
- Neurocrine Biosciences, Inc.$692
- plus $3K from 21 others
What the payments were for
- Food & beverage$8,598100%
- Education$90%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AbbVie(2 entities) | 77 | $1,218 |
| ITI, Inc. (d/b/a Intra-cellular Therapies, Inc.) | 75 | $1,105 |
| Teva Pharmaceuticals USA, Inc. | 57 | $814 |
| Otsuka America Pharmaceutical, Inc. | 41 | $809 |
| Lundbeck LLC | 39 | $738 |
| Neurocrine Biosciences, Inc. | 31 | $692 |
| Vanda Pharmaceuticals Inc. | 23 | $466 |
| Alkermes, Inc. | 25 | $461 |
| Takeda Pharmaceuticals U.S.A., Inc. | 24 | $396 |
| Sunovion Pharmaceuticals Inc. | 36 | $377 |
| Merck | 13 | $262 |
| Johnson & Johnson | 12 | $262 |
| Idorsia Pharmaceuticals US Inc | 17 | $213 |
| Avanir Pharmaceuticals, Inc. | 8 | $131 |
| E.r. Squibb & Sons, L.L.C. | 5 | $105 |
| Eisai Inc. | 6 | $98 |
| Melinta Therapeutics, LLC | 4 | $86 |
| Shionogi Inc | 4 | $76 |
| Viiv Healthcare Company | 3 | $64 |
| Bausch Health US, LLC | 3 | $55 |
| Axsome Therapeutics, Inc. | 2 | $50 |
| Brainsway USA Inc | 1 | $38 |
| OWP Pharmaceuticals, Inc. | 1 | $22 |
| Lilly USA, LLC | 1 | $21 |
| Paratek Pharmaceuticals, Inc. | 1 | $20 |
| Napo Pharmaceuticals Inc | 1 | $15 |
| Theratechnologies Inc. | 1 | $14 |
How this compares
$8,607 in reported general payments places this provider in the 95th percentile of 573 psychiatry providers in Arizona.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| Austedo XrDeutetrabenazine | 16 | $215,135 |
| IngrezzaValbenazine Tosylate | 12 | $96,454 |
| Invega SustennaPaliperidone Palmitate | 12 | $41,962 |
| Bupropion XlBupropion Hcl | 231 | $7,207 |
| Venlafaxine Hcl ErVenlafaxine Hcl | 221 | $6,566 |
| Duloxetine Hcl | 152 | $6,429 |
| TrintellixVortioxetine Hydrobromide | 12 | $5,739 |
| Quetiapine Fumarate | 303 | $4,943 |
| Trazodone Hcl | 331 | $4,533 |
| Aripiprazole | 175 | $4,124 |
| Vilazodone Hcl | 21 | $2,958 |
| Hydroxyzine Hcl | 241 | $2,687 |
| Chlorpromazine Hcl | 12 | $2,464 |
| Fluoxetine Hcl | 139 | $2,333 |
| Lamotrigine | 87 | $2,032 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Teva Pharmaceuticals USA, Inc.Austedo Xr | $814 | $215,13516 claims |
| Neurocrine Biosciences, Inc.Ingrezza | $692 | $96,45412 claims |
| Johnson & JohnsonInvega Sustenna | $262 | $41,96212 claims |
| Takeda Pharmaceuticals U.S.A., Inc.Trintellix | $396 | $5,73912 claims |
| Lilly USA, LLCOlanzapine | $21 | $84254 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 573 psychiatry providers in Arizona.
Other psychiatry in Peoria
- Jason CaplanPhoenix$999K
- Thomas GazdaPhoenix$714K
- Monica BenavidezPhoenix$435K
- Bahar GolestanMesa$234K
- Eric ReimanPhoenix$157K
- Christopher LinskeyPage$100K
- Henry SchulteScottsdale$77K
- Marlene FreemanTucson$59K
- Lauren BonnerScottsdale$44K
- Padma AkingPhoenix$44K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.